Screener
Avalo Therapeutics AVTX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's accounts payable?
- Avalo Therapeutics (AVTX) reported accounts payable of $3.35M in Q2 2026.
- How has Avalo Therapeutics's accounts payable changed year-over-year?
- Avalo Therapeutics's accounts payable increased by 41.5% year-over-year, from $2.37M to $3.35M.
- What is the long-term trend for Avalo Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Avalo Therapeutics's accounts payable has grown at a -44.4% compound annual growth rate (CAGR), from $2.57M to $137K.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Avalo Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude